|
C1ORF198 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.4906964551642E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.80189990600854E-10 |
| Normal-vs-Stage2 |
3.051800E-02 |
| Normal-vs-Stage3 |
3.39519967695878E-10 |
| Normal-vs-Stage4 |
2.81008549762873E-12 |
| Stage1-vs-Stage2 |
9.277800E-01 |
| Stage1-vs-Stage3 |
3.455200E-01 |
| Stage1-vs-Stage4 |
4.667600E-02 |
| Stage2-vs-Stage3 |
6.945200E-01 |
| Stage2-vs-Stage4 |
4.668800E-01 |
| Stage3-vs-Stage4 |
3.370800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.99929986297332E-10 |
| Normal-vs-AfricanAmerican |
1.850800E-01 |
| Normal-vs-Asian |
6.25119999986268E-07 |
| Caucasian-vs-AfricanAmerican |
7.571900E-02 |
| Caucasian-vs-Asian |
8.575200E-01 |
| AfricanAmerican-vs-Asian |
3.640000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.444100E-04 |
| Normal-vs-Female |
7.2863937106149E-13 |
| Male-vs-Female |
1.178390E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.91529999971074E-07 |
| Normal-vs-Age(41-60Yrs) |
3.1354030483044E-11 |
| Normal-vs-Age(61-80Yrs) |
2.81840000004863E-07 |
| Normal-vs-Age(81-100Yrs) |
6.614100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.881250E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.709800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.289200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.037400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.301000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.076200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.27030000002448E-06 |
| Classical-VS-Follicular |
4.579900E-03 |
| Classical-VS-Other |
4.174600E-01 |
| Classical-VS-Normal |
1.95410000403129E-08 |
| Tall-VS-Follicular |
2.640600E-01 |
| Tall-VS-Other |
2.625200E-01 |
| Tall-VS-Normal |
1.62625468647093E-12 |
| Follicular-VS-Other |
3.016600E-01 |
| Follicular-VS-Normal |
1.05090380841943E-11 |
| Other-VS-Normal |
7.716800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.24950050306438E-10 |
| Normal-vs-N1 |
8.3196000089103E-09 |
| N0-vs-N1 |
7.007600E-01 |
|
|
